ARCOMA.ST Stock Analysis
AR
Neutral
Based on Eyestock quantitative analysis, ARCOMA.ST`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Arcoma AB engages in the provision of digital radiographic systems for use in hospitals, clinics, imaging centers, and private practices of all sizes. The company is headquartered in Vaxjo, Kronoberg. The company went IPO on 2014-11-14. The company develops, produces and markets digital radiographic systems. Its products offer digital imaging technology combined with advanced mobile positioning system. The firm's product portfolio comprises: complete radiographic systems available as ceiling suspensions and floor mounted systems, as well as detectors; radiographic system components, such as overhead tube crane, cube, tilting wall stand and radiographic tables; and mobile imaging tables in two series, namely Precision and Elite. Its products are designed for hospitals, clinics, imaging centers and private practices, and available through three market channels: its own brand IMIX, private label distributors and original equipment manufacturers (OEM).